304 related articles for article (PubMed ID: 20162187)
1. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease.
Perez LR; Franz KJ
Dalton Trans; 2010 Mar; 39(9):2177-87. PubMed ID: 20162187
[TBL] [Abstract][Full Text] [Related]
2. Reorganizing metals: the use of chelating compounds as potential therapies for metal-related neurodegenerative disease.
Badrick AC; Jones CE
Curr Top Med Chem; 2011; 11(5):543-52. PubMed ID: 21189128
[TBL] [Abstract][Full Text] [Related]
3. Chelating agents for neurodegenerative diseases.
Ward RJ; Dexter DT; Crichton RR
Curr Med Chem; 2012; 19(17):2760-72. PubMed ID: 22489724
[TBL] [Abstract][Full Text] [Related]
4. Metal Ions in Alzheimer's Disease: A Key Role or Not?
Liu Y; Nguyen M; Robert A; Meunier B
Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
[TBL] [Abstract][Full Text] [Related]
5. Management of oxidative stress and other pathologies in Alzheimer's disease.
Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
[TBL] [Abstract][Full Text] [Related]
6. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations.
Jellinger KA
Int Rev Neurobiol; 2013; 110():1-47. PubMed ID: 24209432
[TBL] [Abstract][Full Text] [Related]
7. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
[No Abstract] [Full Text] [Related]
8. Prochelator strategies for site-selective activation of metal chelators.
Oliveri V; Vecchio G
J Inorg Biochem; 2016 Sep; 162():31-43. PubMed ID: 27297691
[TBL] [Abstract][Full Text] [Related]
9. Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases.
Mckenzie-Nickson S; Bush AI; Barnham KJ
Curr Top Med Chem; 2016; 16(27):3058-3068. PubMed ID: 26881708
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases.
Lanza V; Milardi D; Di Natale G; Pappalardo G
Curr Med Chem; 2018 Feb; 25(4):525-539. PubMed ID: 28521682
[TBL] [Abstract][Full Text] [Related]
11. The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders.
Giampietro R; Spinelli F; Contino M; Colabufo NA
Mol Pharm; 2018 Mar; 15(3):808-820. PubMed ID: 29323501
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
[TBL] [Abstract][Full Text] [Related]
13. The transition metals copper and iron in neurodegenerative diseases.
Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
[TBL] [Abstract][Full Text] [Related]
14. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
[TBL] [Abstract][Full Text] [Related]
15. Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword.
Hegde ML; Hegde PM; Rao KS; Mitra S
J Alzheimers Dis; 2011; 24 Suppl 2(0 2):183-98. PubMed ID: 21441656
[TBL] [Abstract][Full Text] [Related]
16. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional 8-hydroxyquinoline-appended cyclodextrins as new inhibitors of metal-induced protein aggregation.
Oliveri V; Attanasio F; Puglisi A; Spencer J; Sgarlata C; Vecchio G
Chemistry; 2014 Jul; 20(29):8954-64. PubMed ID: 24863958
[TBL] [Abstract][Full Text] [Related]
18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
19. Role of metals in Alzheimer's disease.
Das N; Raymick J; Sarkar S
Metab Brain Dis; 2021 Oct; 36(7):1627-1639. PubMed ID: 34313926
[TBL] [Abstract][Full Text] [Related]
20. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
